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ABSTRACT
Background: Socioeconomic factors influence access to cancer care and survival. 
This study investigated the role of socioeconomic status on the risk of breast cancer 
recurrence and on the delivery of appropriate cancer care (sentinel lymph node biopsy 
and breast-conserving surgery plus radiotherapy), by patients’ age and hormone 
receptor status.
Methods: 3,462 breast cancer cases diagnosed in 2003-2005 were selected from 
7 Italian cancer registries and assigned to a socioeconomic tertile on the basis of the 
deprivation index of their census tract. Multivariable models were applied to assess 
the delivery of sentinel lymph node biopsy and of breast-conserving surgery plus 
radiotherapy within socioeconomic tertiles.
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Results: In the 1,893 women younger than 65 years, the 5-year risk of recurrence 
was higher in the most deprived group than in the least deprived, but this difference 
was not significant (16.4% vs. 12.9%, log-rank p=0.08); no difference was seen in 
women ≥65 years. Among the 2,024 women with hormone receptor-positive cancer, 
the 5-year risk was significantly higher in the most deprived group than in the least 
deprived one (13.0% vs. 8.9%, p=0.04); no difference was seen in cases of hormone 
receptor-negative cancer. The most deprived women were less likely than the least 
deprived women to receive sentinel lymph node biopsy (adjusted odds ratio (ORa), 
0.69; 95% CI, 0.56-0.86) and to undergo breast-conserving surgery plus radiotherapy 
(ORa=0.66; 95% CI, 0.51-0.86). Conclusions: Socioeconomic inequalities affect the 
risk of recurrence, among patients with hormone receptor-positive cancer, and the 
opportunity to receive standard care.
INTRODUCTION
Breast cancer is the most common cancer in women 
worldwide. In Europe, breast cancer is estimated to affect 
more than one in 10 women and accounts for 28.8% of all 
female cancers [1]. In Italy, it accounts for 29% of newly 
diagnosed cancers in women, with 48,000 new cases and 
12,000 deaths attributed to breast cancer in 2015 [2]. 
However, there are large variations in access to standard 
cancer care across Italy, as shown in a population-based 
study involving 14 cancer registries [3].
Variations in cancer survival have been shown to 
depend on differences in socioeconomic status (SES), 
which affects access to cancer screening and high-
quality care and, therefore, influences stage at diagnosis 
and ultimately survival [4, 5]. A recent Italian study [6] 
found that women with low SES had a significantly lower 
odds of receiving an annual mammography or clinical 
breast examination. Another Italian study [7] found that 
a mammography screening programme, with active 
invitation of women from the target population, reduced 
differences in survival. Studies conducted in the United 
Kingdom found that age at diagnosis of breast cancer 
influenced the association between SES and survival, 
as older women with low SES had poorer short-term 
survival than younger women with high SES [8, 9]. In 
addition, there is some epidemiological evidence that low 
SES is associated with breast cancers with an aggressive 
behaviour [10], and differences in SES may determine 
differences in exposures to risk factors for different breast 
cancer subtypes. For instance, women with high SES are 
more likely to use exogenous hormones and have lower 
parity [11, 12], two factors associated with the risk of 
hormone receptor-positive breast cancer. Furthermore, 
researchers from the United States reported that patients 
with hormone receptor-negative breast cancer had lower 
survival rates than patients with hormone receptor-
positive subtypes [13], and the associations between SES 
and both breast cancer incidence [11] and survival [13] 
vary by tumor subtype, with a significant association for 
hormone receptor-positive but not for receptor-negative 
tumors [13].
Only a few studies, all based in the United States, 
have investigated the influence of census-level SES in 
predicting breast cancer outcomes by accounting for 
hormone receptor subtypes and age [11–13]. To further 
understand how SES impacts upon clinical outcomes, 
especially in different health care contexts, we used 
population-based data from Italy to investigate the 
socioeconomic gradient in the risk of disease recurrence 
and in the delivery of appropriate breast care according 
to clinical guidelines, namely sentinel lymph node biopsy 
and breast-conserving surgery plus radiotherapy [14, 15], 
taking into account hormone receptor status and age.
RESULTS
The impact of SES on breast cancer outcomes was 
assessed in a total of 3,358 Italian women diagnosed in the 
period 2003-2005 and followed through to 2010 (Table 
1). The median age at diagnosis was 62 years and 1,893 
women (56.4%) were younger than 65 years. Altogether, 
56.3% of cases lived in Southern Italy, and 43.5% had an 
advanced stage of cancer; 60.3% had a hormone receptor-
positive cancer and 16.2% had a hormone receptor-
negative cancer. Finally, 74.5% of the sample had a 
moderate or poor grade of differentiation, and 67.8% 
received breast-conserving surgery while 31.1% had 
mastectomy.
The associations between SES and both area of 
residence and tumour characteristics were examined 
separately according to the women’s age at diagnosis 
(Table 2). In women younger than 65 years, residence 
area, stage at diagnosis and hormone receptor status were 
not associated with deprivation index (DI). In contrast, 
women in the most deprived category were more likely 
than those in the first tertile to have a poorly differentiated 
cancer (41.2% vs. 33.6%; chi-square p<0.01). Although 
stage at diagnosis was not found to associate with DI (chi-
square, p=0.08), we did observe that women in the most 
deprived category were more likely than those in the least 
deprived category to be diagnosed with advanced tumour 
stage (48.6% vs. 43.5%).
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In women aged ≥65 years, a different pattern 
emerged (Table 2). Residence area was significantly 
associated with DI, with 59.0% of least deprived women 
vs. 43.2% of most deprived women living in the South 
(chi-square, p<0.01). In contrast, stage, hormone receptor 
status, and grade did not associate with DI tertiles in older 
women.
Outcome 1: risk for recurrence
We assessed the cumulative risk for relapse/distant 
metastasis in relation to time since breast cancer diagnosis, 
by age group and hormone receptor status (Figure 2). In 
women younger than 65 years, the cumulative risk of 
recurrence was higher in the most deprived group than in 
the least deprived, but this difference was not significant 
(16.4% vs. 12.9%, log-rank p=0.08, Figure 2a). In women 
≥65 years, there was no relevant difference in cumulative 
risk at 5 years (13.5% in the most deprived vs. 13.2% in 
the least deprived groups; p=0.98, Figure 2b). Analysis by 
hormone receptor status showed that, among women with 
hormone receptor-positive cancer, the 5-year cumulative 
risk for recurrence was significantly higher in the most 
deprived group than in the least deprived one (13.0% 
vs. 8.9%, p=0.04, Figure 2c), and the medium group 
overlapped with the most deprived group. In contrast, in 
hormone receptor-negative breast cancer cases, the 5-year 
cumulative risk was lower in the most deprived than least 
Table 1: Clinical data for 3,358 Italian women with breast cancer
Variable Value
Age, median (IQR), years 62 (50-73)
Area of residence, n (%)
       North-Centre 1,466 (43.7)
       South 1,892 (56.3)
Stage, n (%)
       Early 1,558 (46.4)
       Advanced 1,462 (43.5)
       Unknown 338 (10.1)
Hormone receptor status, n (%)
       Positive 2,024 (60.3)
       Negative 543 (16.2)
       Other or unknown 791 (23.6)
Grade of differentiation, n (%)
       Well 334 (10.0)
       Moderate 1,333 (39.7)
       Poor 1,170 (34.8)
       Unknown 521 (15.5)
Surgery, n (%)
       Breast-conserving surgery 2,277 (67.8)
       Mastectomy 1,044 (31.1)
       None or unknown 37 (1.1)
Laterality, n (%)
       Right 1,547 (46.1)
       Left 1,652 (49.2)
       Bilateral 46 (1.4)
       Unknown 113 (3.4)
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Table 2: Characteristics of 3,358 women with breast cancer, by age and deprivation index tertile
Variable
Deprivation index tertile, n (%)a
Total pb
1 (least deprived) 2 3 (most deprived)
All patients 1,304 (38.8) 983 (29.3) 1,071 (31.9) 3,358
<65 years (n=1,893)
 Area
  North-Centre 271 (38.4) 249 (44.4) 262 (41.9) 782 (41.3)
0.09
  South 435 (61.6) 312 (55.6) 364 (58.2) 1,111 (58.7)
 Stage
  Early 353 (50.0) 300 (53.5) 286 (45.7) 939 (49.6)
0.08  Advanced 307 (43.5) 233 (41.5) 304 (48.6) 844 (44.6)
  Unknown 46 (6.5) 28 (5.0) 36 (5.8) 110 (5.8)
 Hormone receptor subtype
  Positive 426 (60.4) 333 (59.4) 408 (65.2) 1,167 (61.7)
0.25  Negative 126 (17.9) 108 (19.3) 98 (15.7) 332 (17.5)
  Other or unknown 154 (21.8) 120 (21.4) 120 (19.2) 394 (20.8)
 Grade of differentiation
  Well 72 (10.2) 68 (12.1) 54 (8.6) 194 (10.2)
<0.01
  Moderate 285 (40.4) 240 (42.8) 252 (40.3) 777 (41.1)
  Poor 237 (33.6) 191 (34.1) 258 (41.2) 686 (36.3)
  Unknown 112 (15.9) 62 (11.1) 62 (9.9) 236 (12.5)
 Total 706 (37.3) 561 (29.6) 626 (33.1) 1,893 (100)
≥65 years (n=1,465)
 Area
  North-Centre 245 (41.0) 186 (44.1) 253 (56.9) 684 (46.7)
<0.01
  South 353 (59.0) 236 (55.9) 192 (43.2) 781 (53.3)
 Stage
  Early 240 (40.1) 177 (41.9) 202 (45.4) 619 (42.3)
0.47  Advanced 261 (43.7) 183 (43.4) 174 (39.1) 618 (42.2)
  Unknown 97 (16.2) 62 (14.7) 69 (15.5) 228 (15.6)
 Hormone receptor subtype
  Positive 337 (56.4) 247 (58.5) 273 (61.4) 857 (58.5)
0.49  Negative 90 (15.1) 57 (13.5) 64 (14.4) 211 (14.4)
  Other or unknown 171 (28.6) 118 (28) 108 (24.3) 397 (27.1)
 Grade of differentiation
  Well 51 (8.5) 39 (9.3) 50 (11.1) 140 (9.5)
0.16
  Moderate 221 (37.0) 175 (41.5) 160 (36.0) 556 (38.0)
  Poor 198 (33.1) 126 (29.9) 160 (36.0) 484 (33.0)
  Unknown 128 (21.4) 82 (19.3) 75 (16.9) 285 (19.5)
 Total 598 (40.8) 422 (28.8) 445 (30.4) 1,456 (100)
aTertiles were calculated at the population level for each region.
bChi-square test.
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deprived women, but this difference was not significant 
(21.0% vs. 27.5%, p=0.54, Figure 2d). Finally, the 5-year 
cumulative risk was lower in hormone receptor-positive 
than in hormone receptor-negative cases in all DI tertiles 
and altogether (10.7% vs. 24.5%, p<0.01).
Table 3 shows the adjusted hazard ratios (HRs) 
for recurrence according to five Cox regression models. 
Model 1, which considered all 3,358 cases and adjusts by 
stage, age, and hormone receptor status, shows that the 
most deprived women had a non-significant 18% higher 
risk of recurrence than the least deprived ones (HR=1.18; 
95% CI, 0.96-1.46). A late stage at diagnosis carried a 
significantly higher HR of recurrence than early stage 
(HR=3.29; 95% CI, 2.69-4.03), and hormone receptor-
negative cancers carried a significantly higher risk than 
hormone receptor-positive subtypes (HR=2.41; 95% CI, 
1.95-2.98). Overall, 0.8% of cases were lost of follow-up.
The analysis was repeated with patients stratified by 
age. In the younger class (Model 2a), SES affected the risk 
of recurrence, as belonging to the most deprived group 
carried a 29% higher risk of recurrence after adjusting 
for stage and hormone receptor status (HR=1.29; 95% 
CI, 0.99-1.68). In contrast, the risk of recurrence in older 
women was not affected by SES (Model 2b). For both age 
classes, a late stage at diagnosis carried a significant higher 
risk of recurrence than did an early stage: for women 
<65 years, HR=3.05 (95% CI, 2.37-3.92); for women 
≥65 years, HR=3.72 (95% CI, 2.74-5.24). Moreover, a 
significantly higher risk was found for hormone receptor-
negative cancers than hormone receptor-positive ones: 
for women <65 years, HR=2.31 (95% CI, 1.76-3.02); for 
women ≥65, HR=2.59 (95% CI, 1.82-3.70).
In a third analysis, patients were stratified according 
to the hormone receptor status of their cancers. In hormone 
receptor-positive cases (Model 3a, adjusted by age and 
stage), the most deprived women had a higher risk of 
recurrence (HR=1.44; 95% CI, 1.07-1.93) than the least 
deprived women. Model 3b shows that there was no 
significant effect of SES on the risk of recurrence in hormone 
receptor-negative cases (HR=0.74; 95% CI, 0.49-1.14). Late 
stage posed a significantly higher risk of recurrence for both 
hormone receptor-positive women (HR=3.13; 95% CI, 2.36-
4.15) and hormone receptor-negative women (HR=3.78; 
95% CI, 2.54-5.62). No differences were seen by age.
In order to investigate whether socioeconomic 
deprivation influenced the outcome of women eligible 
to participate in mass screening programmes, we also 
estimated HRs for three age classes: <50 years, 50-69 
years, and ≥70 years; the central class represents the 
target population of the screening programme in Italy. 
We found a significant association between advanced 
stage at diagnosis and SES in the youngest age class 
(Supplementary Table 1), and a significant association 
between grade and SES in the central age class 
(Supplementary Table 2). No association between SES 
and stage or grade was found in the oldest age group, a 
significant association was found with the residence area 
(Supplementary Table 3). However, in multivariable 
regression models adjusted for stage and hormone 
receptor status, no significant effect of SES on the risk of 
recurrence was found in any age group (Supplementary 
Table 4).
Outcomes 2 and 3: appropriateness of care
To investigate the relationship between SES and 
the probability of receiving sentinel lymph node biopsy 
(SLNB, Outcome 2), we analysed 2,434 cases, selected on 
the basis of clinical characteristics (Figure 1), for whom 
this procedure is recommended. Overall, 810 women 
(33.3%) received SLNB. The percentages of women who 
underwent SLNB were 29.8% in the most deprived group 
and 34.8% in the least deprived one (Table 4). The odds 
ratio (ORa) for receiving SLNB, adjusted by residence 
area, age, and hormone receptor status, was significantly 
lower in the most deprived women than in the least 
deprived (ORa=0.69; 95% CI, 0.56-0.86). SLBN was less 
commonly done in women resident in the South vs. those 
living in the North-Centre (ORa=0.27; 95% CI, 0.22-
0.32), in older than younger women (ORa=0.57; 95% CI, 
0.47-0.69), and in women with hormone receptor-negative 
cancer (ORa=0.51; 95% CI, 0.40-0.67).
To investigate the relationship between SES and 
the chance to receive breast-conserving surgery plus 
radiotherapy (BCS+RT, Outcome 3), we analysed 1,359 
breast cancer cases (Table 4) selected on the basis of 
clinical characteristics (Figure 1), for whom this procedure 
is recommended. Overall, 861 women (63.4%) received 
this treatment. The percentages of women who received 
BCS+RT were 65.3% in the least deprived group and 
56.0% in most deprived group, with higher rates in the 
central group. The ORa of receiving BCS+RT, adjusted 
by area, age and hormone receptor status, was significantly 
lower in the most deprived women than in the least 
deprived (ORa=0.66; 95% CI, 0.51-0.86). Furthermore, 
older women were less likely to receive BCS+RT than 
younger women (ORa=0.45; 95% CI, 0.36-0.57). Living 
in the South of Italy and having a hormone receptor-
negative cancer subtype did not affect the opportunity to 
receive BCS+RT.
DISCUSSION
This study examined the impact of SES, scored with 
a deprivation index, on three breast cancer outcomes in 
Italy. Analysing the first outcome, we found that, for all 
cases, the most deprived women had a non-significant 
18% higher risk of recurrence than the least deprived 
ones; however, within the group of hormone receptor-
positive cancer, the most deprived ones had a significantly 
higher risk of recurrence than the least deprived. Also, 
for women younger than 65 years, the most deprived had 
a significantly higher frequency of poorly differentiated 
breast cancer at diagnosis and, consequently, a higher risk 
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of recurrence than the least deprived cases. Investigating 
Outcomes 2 and 3, we observed that women in the 
most deprived tertile received SNLB and BCS+RT less 
frequently than the least deprived women.
Italy has a public national health care system, 
financed by general taxation, which should “guarantee the 
uniform provision of comprehensive care and assistance 
throughout the country” [16]. However, there are 
differences in the organisation and provision of health care 
among the 20 regions, because the central government 
defines the “essential levels of care” that are guaranteed to 
all residents, while the regions, which differ in economic 
resources, specialised hospitals and health expenditures, 
are responsible for administering the publicly financed 
care. SLNB and BCS+RT should be performed regardless 
of a patient’s ability to pay. In reality, however, they are 
provided mostly by specialised cancer centres (which tend 
to be found in wealthier areas) rather than in low-volume 
hospitals. Thus, although delivery of these forms of care 
should not be influenced by SES, this study showed that 
the most deprived women were less likely to undergo 
these procedures. One explanation for this difference is 
the out-of-pocket costs that cancer survivors must bear in 
order to reach specialised cancer hospitals [17]. Another 
explanation is that, in this study, the DI was assigned to 
cases according to their area of residence; thus a patient 
was defined as “deprived” because she lives in a deprived 
area. As a result, more advantaged patients, who have 
relatively little trouble affording these expenses and who 
may live closer to specialised centres, have more chances 
to receive standard care.
Figure 1: Case selection for three different outcomes. SES, socioeconomic status; SLNB, sentinel lymph node biopsy; BCS+RT, 
breast-conserving surgery plus radiotherapy.
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Studies in the United States [18] and Italy [19] 
found that advanced age was associated with getting less 
care according to treatment guidelines, irrespective of 
comorbidities, stage, or tumour characteristics. Moreover, 
in the United States, women aged 65 years or more 
received radiation therapy less frequently than younger 
women [18]. Our results are consistent with these studies, 
in that we also found that elderly patients were treated 
less frequently with BCS+RT than younger women. 
Furthermore, we observed that, within a single age group, 
socioeconomic deprivation independently affected the 
possibility of receiving this standard treatment.
This study found that SLNB was performed less 
frequently in older than younger patients and in the most 
deprived than the least deprived. Radhakrishnan et al. [20] 
reported that, in the United States, old age was associated 
with a decreased odds of receiving SLNB for early breast 
cancer. This undertreatment does not necessarily result in 
worse outcomes. In fact, some studies found no effect on 
disease-free survival in elderly patients in whom lymph 
node evaluation was omitted [21–23].
Our study revealed that SES affects the risk of 
disease recurrence differentially according to breast 
cancer subtype, with a significant difference only in the 
hormone receptor-positive group. In the reverse Kaplan-
Meier analysis for cumulative probability (Figure 2c), the 
curve for least deprived women is always below that for 
the most deprived women, which overlaps and crosses the 
curve for the medium deprived women. This effect may 
be due to the fact that calculation of the medium curve 
is more influenced by neighboring values than the two 
others. Furthermore, these curves derive from univariate 
analyses, not adjusted for any prognostic factors. When 
we estimated Cox models adjusting for stage at diagnosis 
and age, we found that the most deprived women had 
a significantly higher risk than the least deprived in the 
subgroup of hormone receptor-positive cancer but not in 
that of hormone receptor-negative cancer. We do not have 
an explanation for this phenomenon, and the relatively 
low number of women with hormone receptor-negative 
breast cancer prevents definitive conclusions. However, 
this difference may be explained by the fact that the latter 
Figure 2: Cumulative risk for locoregional relapse or distant metastasis, by age and hormone receptor status.
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subtype (which includes triple-negative breast cancer and 
a large part of HER2-positive breast cancer) is intrinsically 
more aggressive, less respondent to therapies, and likely 
diagnosed at a more advanced stage than hormone 
receptor-positive cancers [24]. Therefore, hormone 
receptor-negative tumours carry a high recurrence risk, 
regardless of SES.
This finding is consistent with another study by 
Akinyemiju et al. [13], reporting that the higher mortality 
risk in hormone receptor-negative cancers did not change 
after adjustment for SES.
Furthermore, a US study [25] found that survival 
differences by ethnicity are more marked for less 
aggressive cancers than more aggressive ones. Thus, black 
women in the United States had lower survival than whites 
for most breast cancer subtypes, but among the aggressive 
triple-negative subtype, black women had similar survival 
to women of other races, suggesting that this subtype of 
breast cancer has worse prognosis regardless of other 
factors as ethinicity.
In our study, we did not find a significant association 
between SES and hormone receptor subtype. In contrast, 
Andaya et al. [26] found that, in the United States, low 
SES areas tended to have a higher prevalence of cancers 
with hormone receptor-negative status than did the more 
affluent areas. We found that, in the <65 years age group, 
women in the most deprived category were more likely 
than the least deprived to be diagnosed with advanced 
tumour stage and with a poorly differentiated cancer 
and had a non-significant increased risk of recurrence. 
The association between socioeconomic deprivation and 
advanced stage may depend on a diagnostic delay due 
to scarce access to diagnostic facilities, while wealthier 
persons may have easier access to diagnostic facilities, 
health information and medical examinations.
Several European studies found that a population-
based breast screening programme had a significant 
impact on the socioeconomic gradient in survival [27–29]. 
In Italy, screening programmes covered approximately 
75% of the female population aged 50-69 years in 2005 
[30]. After implementation of the screening programme 
in Emilia-Romagna Region, the survival disadvantage of 
low educated patients (compared with highly educated 
patients) disappeared among women in the age group 
Table 3: Adjusted hazard ratios (HRs) for recurrence by age and hormone receptor status, from five Cox regression 
models
Variable
Age Hormone receptor
p
Model 1a Model 2ab Model 2bc Model 3ad Model 3be
<65 years ≥65 years Positive Negative
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI)
Deprivation 
index tertile
 1 (least) 1 1 1 1 1
 2 1.07 (0.86-1.34) 0.52 1.13 (0.85-1.50) 0.40 1.00 (0.71-1.42) 0.98 1.18 (0.85-1.63) 0.98 0.83 (0.55-1.26) 0.40
 3 (most) 1.18 (0.96-1.46) 0.11 1.29 (0.99-1.68) 0.06 1.04 (0.74-1.46) 0.83 1.44 (1.07-1.93) 0.02 0.74 (0.49-1.14) 0.17
Stage
 Early 1 1 1 1 1
 Late 3.29 (2.69-4.03) <0.01 3.05 (2.37-3.92) <0.01 3.72 (2.64-5.24) <0.01 3.13 (2.36-4.15) <0.01 3.78 (2.54-5.62) <0.01
 Unknown 1.63 (1.13-2.37) <0.01 1.77 (1.06-2.98) 0.03 1.57 (0.92-2.70) 0.10 2.17 (1.23-3.81) <0.01 1.69 (0.71-4.05) 0.24
Age
 <65 years 1 - - - - 1 1
 ≥65 years 0.98 (0.81-1.18) 0.86 - - - - 0.95 (0.73-1.23) 0.70 1.03 (0.72-1.48) 0.86
Hormone 
receptor status
 Positive 1 1 1 - - - -
 Negative 2.41 (1.95-2.98) <0.01 2.31 (1.76-3.02) <0.01 2.59 (1.82-3.70) <0.01 - - - -
  Other or 
unknown 1.52 (1.21-1.90) <0.01 1.48 (1.11-1.97) <0.01 1.58 (1.11-2.24) 0.01 - - - -
aAll cases (3,358) were included in this model. b1893 cases aged <65 years were selected for this model adjusted for stage and hormone receptor status. c1465 
cases aged ≥65 years were selected for this model adjusted for stage and hormone receptor status. d2,024 hormone receptor-positive cases were selected for 
this model adjusted for stage and age. e543 hormone receptor-negative cases were selected for this model adjusted for stage and age.
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invited to screening [7]. Similar results were found by a 
study conducted in the City of Florence [31]. Furthermore, 
in the City of Turin, breast cancer patients diagnosed in a 
screening programme received good-quality breast cancer 
care without differences by SES [32].
We did not find a significant association between 
SES and the risk of disease recurrence in the group of 
women aged less than 50 years or in the other two age 
groups. We found that women with low SES were more 
likely to have a more advanced tumour stage only in the 
youngest age group, so we can assume that the effect of 
SES on tumour stage may be attenuated for women aged 
between 50 and 69 years old, who represent the target 
of the screening programme. A Scottish study [8] that 
investigated the effect of SES on breast cancer survival 
found survival differences of 10% between rich and 
deprived women, but there was no evidence that the effect 
of deprivation on survival varied significantly by age 
group. A more recent study in England [9] reported that 
the socioeconomic deprivation gap in survival widened 
with increasing age at diagnosis.
Strengths and weakness
Our analysis was strengthened by the use of the 
population-based EUROCARE 5-High Resolution 
database, which provides a representative sample of all 
breast cancer cases incident in the registry areas. This 
feature allowed our study to avoid selection bias due to 
recruitment in a single institution. Furthermore, for the 
first time in Italy, we linked population-based data with 
information on care and treatment to the census tract DI 
database [33], in order to attribute to each cancer case a 
SES category. A limitation of our study regards the use of 
a census tract DI rather than an individual DI because, as 
argued by Moriceau et al. [34], the association between 
SES and cancer survival, where it exists, was stronger 
when SES was assessed individually [35] than according 
to the census tracts [36]. Indeed, people can live in a 
deprived area without being deprived themselves. Another 
limitation of this study is that we did not have information 
on comorbidities, screening, or lifestyle and environmental 
factors that interact with SES and potentially affect 
prognosis and therefore survival.
We decided to categorise breast cancer subtypes 
into two main groups, hormone receptor positive and 
negative, instead of using a more detailed classification, 
e.g. distinguishing luminal types, and incorporating HER2 
and ki67. We used this broad classification to have an 
adequate number of cases in each analysed grouping, to 
reduce variability due to low numbers.
In summary, our study confirms the existence of 
health inequalities across Italy and suggests that those 
Table 4: Cases receiving appropriate care and results of multivariable logistic regression
SLNB (n = 2,434) BCS+RT (n = 1,359)
n (%) ORa (95% CI) p n (%) ORa (95% CI) p
Deprivation index 
tertile
 1 (least) 318 (34.8) 1 326 (65.3) 1
 2 256 (35.2) 0.93 (0.75-1.16) 0.53 277 (69.4) 1.17 (0.88-1.56) 0.29
 3 (most) 236 (29.8) 0.69 (0.56-0.86) <0.01 258 (56.0) 0.66 (0.51-0.86) <0.01
Area
 North-Centre 542 (47.4) 1 485 (63.7) 1
 South 268 (20.8) 0.27 (0.22-0.32) <0.01 376 (63.0) 0.93 (0.73-1.17) 0.52
Age
 <65 years 446 (36.6) 1 466 (72.0) 1
 ≥65 years 364 (29.9) 0.57 (0.47-0.69) <0.01 395 (55.5) 0.45 (0.36-0.57) <0.01
Hormone receptor 
status
 Positive 573 (35.7) 1 594 (64.9) 1
 Negative 96 (23.2) 0.51 (0.40-0.67) <0.01 136 (61.5) 0.80 (0.59-1.10) 0.17
  Other or 
unknown 141 (34.1) 0.80 (0.63-1.02) 0.08 131 (59.0) 0.75 (0.55-1.02) 0.07
ORa, adjusted odds ratio; CI, confidence interval; SLNB, sentinel lymph node biopsy; BCS+RT, breast-conserving surgery 
plus radiotherapy.
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inequalities affect breast cancer outcomes, such as risk 
of recurrence and opportunity to receive standard care. 
Through the use of a census tract DI, this study identified, 
within small geographic areas, groups of people to whom 
actions to reduce socioeconomic inequalities should be 
directed, in order to extend the availability of appropriate 
care and correct management of breast cancer patients.
MATERIALS AND METHODS
Study design and data sources
This study was conducted in the context of 
EUROCARE (European Cancer Registry-Based Study 
on Survival and Care of Cancer Patients) [37] and was 
based on data already collected for a EUROCARE-5 
High Resolution Study of breast cancer survival in Italy 
[38]. According to the EUROCARE-High Resolution 
study protocol [39], a cancer registry may participate if 
it is able to provide data for at least 500 cases of primary 
breast cancer, diagnosed in women (≥15 years old) in the 
period 2003–2005 and followed to the end of 2010. Of 
the 34 cancer registries belonging to the Italian Cancer 
Registry Association (AIRTum) [40], nine contributed 
data for the High Resolution study and seven of these 
nine cancer registries also participated in the present 
study. Three of the participating cancer registries cover 
areas of North-Central Italy: Modena Cancer Registry and 
Romagna Cancer Registry (Region of Emilia-Romagna), 
and Umbria Cancer Registry (Umbria). The other four 
registries cover Southern Italy: Napoli Cancer Registry 
(Campania) and the registries of Palermo, Ragusa, Trapani 
(Sicily).
Cases were extracted from the AIRTum database by 
a randomised procedure balanced for each participating 
registry and year of diagnosis. From each participating 
cancer registry, we obtained clinical and socioeconomic 
data for about 500 cases, according to the EUROCARE-5 
High Resolution Study protocol [39], for a total of 3462 
cases. For the present study, cancer registries were asked 
to provide the 2001 census tract [41] of residence for each 
case.
Clinical data
For each case included in the study, we obtained 
information on age and stage at diagnosis, clinical and 
pathological characteristics of the tumour, treatments given 
(breast-conserving surgery, mastectomy, radiotherapy), 
and data on disease progression and life status (alive or 
dead) up to 5 years after the diagnosis.
Age at diagnosis was dichotomised into two 
classes (<65 years, ≥65 years) to compare young and 
elderly people, while three age classes (<50 years, 
50–69 years, ≥70 years) were used to examine the 
impact of breast cancer screening programmes available 
for women in the 50–69 year group [30]. Stage at 
diagnosis was coded according to the TNM system 
(sixth edition) [42] and categorised as early stage 
(T1N0M0 or T2-3N0M0), advanced stage (T1-3N+M0 
or T4anyNM0-1), or unknown. Tumour grade was 
classified as well differentiated, moderately differentiated, 
poorly differentiated, or unknown. Tumour laterality was 
classified as right, left, bilateral, or unknown.
Tumours were scored positive for estrogen or 
progesterone receptor expression when 10% or more 
of neoplastic cells had nuclear immunohistochemical 
staining. Hormone receptor status was then considered 
hormone receptor positive when the tumour was positive 
for both estrogen receptor and progesterone receptor, 
hormone receptor negative when staining was negative 
for both receptors, and other in the remaining cases; use 
of this broad classification was motivated by the need to 
have an adequate number of cases in each group.
Socioeconomic status data
The SES of each patient was expressed using the 
Italian deprivation index (DI), a score recently developed 
by some of us [33]. This index is a sum of the frequencies 
of five census variables that reflect social and material 
deprivation: low level of education, unemployment, 
one-parent family, home rental and home overcrowding. 
Current values of the index are based on data from the 
2001 Italian population census and refer to 352,605 census 
tracts (average of 169 inhabitants in a mean area of 0.6 
km²). Because the Italian DI at census-tract level was 
shown to represent individual deprivation [43], it was used 
as the socioeconomic indicator for individual patients in 
this study. The census tract in which each patient lived at 
the time of diagnosis was provided by participating cancer 
registries, and the corresponding DI was obtained from the 
database held by Caranci et al. [33].
To study the effects of socioeconomic status, we 
divided the population in tertiles, a classification system 
that provides clear contrast between groups [32]. To this 
aim, we first determined cut-off values of DI for tertiles 
in each of the four Italian regions considered in the study. 
Then, patients were assigned to one of these tertiles on 
the basis of the DI for their census tract. The first tertile 
included the least deprived cases and the third tertile had 
the most deprived cases.
Outcome variables and case selection
In order to investigate the influence of SES 
on prognosis and adhesion to selected clinical 
recommendations, we considered three primary outcomes: 
1) Cumulative risk of recurrence, by age and hormone 
receptor status; 2) Proportion of cases that underwent 
sentinel lymph node biopsy (SLNB); and 3) Proportion 
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of T1-2N0M0 cases that underwent breast-conserving 
surgery plus radiotherapy (BCS+RT).
To study these outcome variables, a series of 
increasingly stringent exclusion criteria were applied to 
select cases from the initial study population of 3,462 
cases (Figure 1). First, we excluded 70 cases for whom 
data on SES were missing, 28 cases who were known 
to the registry only because breast cancer had been 
mentioned on their death certificates, and 6 cases with 
benign breast disease. Therefore, 3,358 women were 
analysed for Outcome 1 (risk of recurrence).
To study Outcomes 2 and 3, we further excluded 
374 cases with stage T4 or unknown T stage (Tx), 232 
cases with metastatic disease at diagnosis (M1), and 79 
cases that were not operated. These exclusion criteria left 
a set of 2,673 cases for analysis of the appropriateness 
of care (Figure 1). To study Outcome 2 (proportion 
of cases receiving SLNB), we excluded 143 cases for 
whom information on SLNB or axillary dissection was 
incomplete, 59 cases with bilateral breast cancer or 
unknown laterality (this decision was taken because we 
did not find strong recommendations regarding delivery 
of SLNB to bilateral breast cancer), and 37 cases in whom 
clinical examination revealed positive axillary lymph 
node status, in accordance with clinical guidelines; thus 
2,434 selected cases were assessed for Outcome 2. Finally, 
for Outcome 3 (proportion of cases receiving BCS+RT), 
we excluded cases with stage T3, nodal metastases at 
diagnosis (in accordance with ESMO guidelines [15]), 
and all cases from the Trapani Cancer Registry because 
more than 50% had missing or incomplete information on 
radiotherapy. After these exclusions, 1,359 cases with T1-
2N0M0 disease were available for analysis. The groups 
assessed for Outcomes 1, 2 and 3 were similar in baseline 
characteristics.
Statistical analysis
Descriptive statistics were calculated to summarise 
demographic and prognostic factors of patients. The 
associations between DI tertiles and both residence area 
and various tumour characteristics were assessed using the 
chi-square test. These analyses were done separately for 
patients <65 years and those ≥65 years of age at diagnosis. 
Tests were two-sided and a difference with a p<0.05 was 
considered statistically significant.
The cumulative risks of recurrence in the first 5 years 
after diagnosis, for different DI tertiles, were estimated 
using a reverse Kaplan-Meier method for cumulative 
probability. Every locoregional relapse or distant 
metastasis was considered an event, and time between 
diagnosis and event was considered as survival time. Log-
rank tests were used to evaluate differences by DI tertiles. 
Cox proportional hazard models were applied to study the 
impact of SES on the risk of developing progression of 
disease. The impact of prognostic factors was estimated by 
subsequently adding in the models age, stage and hormone 
receptor status. We stratified by hormone receptor status 
because one study found that hormone receptor-negative 
cancers were more frequent in deprived areas and carried 
a poor prognosis independent of SES [11]. We stratified 
by age because, in younger women, the distribution of 
cases by SES and prognostic factors (stage and grade) 
showed a higher percentage of cases with advanced stage 
(48.6% vs. 43.5%) and poorly differentiated grade (33.6% 
vs. 42.2%) in the most deprived class than in the least 
deprived. Therefore the relation between SES and disease 
recurrence may be influenced by age. Multivariable 
logistic regression models were used to investigate 
the association between DI tertiles and the delivery of 
appropriate care. In particular, we assessed the delivery of 
SLNB and BCS+RT to the cases assessed for Outcomes 2 
and 3, respectively, controlling for age, hormone receptor 
status, and residence area. We included in the model those 
variables that had a significant impact on outcome in the 
univariate analysis and that are known risk factors for that 
outcome. Statistical analyses were carried out using the 
Stata statistical package (version 12) and R (version 3.3.1).
Abbreviations
BCS+RT, breast-conserving surgery plus 
radiotherapy; DI, deprivation index; SES, socioeconomic 
status; SLNB, sentinel lymph node biopsy.
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